Methylation Sciences Inc (MSI), based in Canada, is a company focused on developing pharmaceuticals based on molecules which are proven to be clinically effective but which have yet to be exploited in major pharmaceutical markets.
SAMe
MSI is actively developing proprietary formulations of naturally-occurring S-Adenosyl Methionine (SAMe) as a stand-alone pharmaceutical product and/or in combination (adjunctive) with current therapies for the treatment of major depressive disorder.
Efficacy and safety profile
A long record of clinical use and large body of credible, supporting research indicates that SAMe is safe, well tolerated and clinically effective. Our proprietary formulations of SAMe exhibit a broad range of benefits, including extended release, improved PK profile and reduced dosing requirements to achieve a therapeutic response.
www.methylationsciences.com
SAMe
MSI is actively developing proprietary formulations of naturally-occurring S-Adenosyl Methionine (SAMe) as a stand-alone pharmaceutical product and/or in combination (adjunctive) with current therapies for the treatment of major depressive disorder.
Efficacy and safety profile
A long record of clinical use and large body of credible, supporting research indicates that SAMe is safe, well tolerated and clinically effective. Our proprietary formulations of SAMe exhibit a broad range of benefits, including extended release, improved PK profile and reduced dosing requirements to achieve a therapeutic response.
www.methylationsciences.com
Location: United Kingdom, England
Employees: 51-200
Total raised: $48.37M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Inventages | inventages... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.10.2016 | - | $30M | - |
| 29.09.2011 | Series A | $18.37M | - |
Mentions in press and media 3
| Date | Title | Description |
| 08.10.2016 | Quark Venture-backed MSI Raises $30M | Quark Venture Inc., a venture capital company, announced a US$30 million investment in MSI (MSI Methylation Sciences Inc.), a clinical-stage pharmaceutical company, that will enable MSI to advance development of an oral, small molecule ther... |
| 06.10.2016 | Methylation Sciences Raises US$30M in Funding | Methylation Sciences Inc., a Vancouver, BC-based clinical-stage pharmaceutical company, raised US$30m in funding. Quark Venture made the investment through its Global Health Sciences Venture Fund. The company intends to use the funds to adv... |
| 29.09.2011 | MSI Methylation Sciences Raises €13.5M in Series A Financing | MSI Methylation Sciences, Inc., a Vancouver, British Columbia Canada-based company focused on developing S-Adenosyl Methionine (SAMe), a prescription drug used as a dietary supplement, has raised €13.5m (CDN$19m) in a Series A financing. Th... |